Novel therapies in the treatment of ulcerative colitis.
Ulcerative colitis is a chronic inflammatory disease of the colon of unknown cause. Its course is one of relapse and remission and requires therapy for both the induction and maintenance of remission. Progress in the fields of genetics and immunology affords important advances in our understanding of the inflammatory process. Traditional therapy for ulcerative colitis with nonspecific anti-inflammatories remains our gold standard. This review examines the most recent compounds in development for the treatment of ulcerative colitis, including data from early clinical trials and the potential clinical impact of future entities.
Tuvlin
Jeffrey A
JA
Department of Medicine, Division of Gastroenterology, University of Chicago, 5841 South Maryland Ave, MC 4076, Chicago, IL 60637, USA.
Kane
Sunanda V
SV
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000975:Antioxidants / Q000627:therapeutic use; D001393:Azoles / Q000627:therapeutic use; D001781:Blood Component Removal; D002986:Clinical Trials as Topic; D003093:Colitis, Ulcerative / Q000188:drug therapy / Q000628:therapy*; D016207:Cytokines / Q000627:therapeutic use; D051526:Fibroblast Growth Factor 10; D005346:Fibroblast Growth Factors / Q000627:therapeutic use; D006728:Hormones / Q000627:therapeutic use; D006801:Humans; D016566:Organoselenium Compounds / Q000627:therapeutic use; D019936:Probiotics / Q000627:therapeutic use; D011480:Protease Inhibitors / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal; D000975:Antioxidants; D001393:Azoles; D016207:Cytokines; D051526:Fibroblast Growth Factor 10; D006728:Hormones; D016566:Organoselenium Compounds; D011480:Protease Inhibitors; D005346:Fibroblast Growth Factors; C114695:BXT 51072